Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer

被引：4

作者：

Takada, Koji ^{[1
]}

Kashiwagi, Shinichiro ^{[1
]}

Goto, Wataru ^{[1
]}

Asano, Yuka ^{[1
]}

Takahashi, Katsuyuki ^{[2
]}

Morisaki, Tamami ^{[1
]}

Takashima, Tsutomu ^{[1
]}

Tomita, Shuhei ^{[2
]}

Hirakawa, Kosei ^{[1
]}

Ohira, Masaichi ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan

[2] Osaka City Univ, Grad Sch Med, Dept Pharmacol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2018年 / 144卷 / 08期

基金：

日本学术振兴会;

关键词：

Quality of life; Breast cancer; Prognostic marker; Preoperative chemotherapy; QOL-ACD-B; QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; PROGNOSTIC VALUE; SCORES; SURVIVAL; THERAPY; ADJUVANT; NEOADJUVANT; VALIDATION; CARES;

D O I：

10.1007/s00432-018-2670-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Quality-of-life (QOL) has been reported to affect the prognosis of many types of cancer, and several studies used various QOL assessment tools to determine the relationship between QOL and cancer prognosis. In this study, QOL-Questionnaire for Cancer Patients Treated with Anti-Cancer Drugs-the Breast (QOL-ACD-B) was modified to be suitable for preoperative chemotherapy (POC) and was named the QOL-ACD-BP. A total of 300 patients were treated with POC after being diagnosed with breast cancer between February 2007 and December 2016 at our institute. We evaluated novel evaluation scale for QOL (QOL-ACD-BP) before and after POC in a retrospective manner. In the multivariate analysis with overall survival, the high QOL before [p = 0.048, hazard ratio (HR) 0.441] or after POC (p = 0.030, HR 0.273) was an independent factor. Our study shows that QOL after POC may also affect prognosis and supported the importance of maintaining QOL in cancer treatment. In patients with breast cancer treated with POC, QOL-ACD-BP, which is a new QOL evaluation index, was found to be a useful tool for predicting the patients' prognosis.

引用

页码：1547 / 1559

页数：13

共 36 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial [J].

Aihara, Tomohiko ;

Yokota, Isao ;

Hozumi, Yasuo ;

Aogi, Kenjiro ;

Iwata, Hiroji ;

Tamura, Motoshi ;

Fukuuchi, Atsushi ;

Makino, Haruhiko ;

Kim, Ryungsa ;

Andoh, Masashi ;

Tsugawa, Koichiro ;

Ohno, Shinji ;

Yamaguchi, Takuhiro ;

Ohashi, Yasuo ;

Watanabe, Toru ;

Takatsuka, Yuichi ;

Mukai, Hirofumi .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (02) :337-343

[3] Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer [J].

Asano, Y. ;

Kashiwagi, S. ;

Goto, W. ;

Kurata, K. ;

Noda, S. ;

Takashima, T. ;

Onoda, N. ;

Tanaka, S. ;

Ohsawa, M. ;

Hirakawa, K. .

BRITISH JOURNAL OF SURGERY, 2016, 103 (07) :845-854

[4] Quality of life in patients undergoing systemic therapy for advanced breast cancer [J].

Bottomley, A ;

Therasse, P .

LANCET ONCOLOGY, 2002, 3 (10) :620-628

[5] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].

CELLA, DF ;

TULSKY, DS ;

GRAY, G ;

SARAFIAN, B ;

LINN, E ;

BONOMI, A ;

SILBERMAN, M ;

YELLEN, SB ;

WINICOUR, P ;

BRANNON, J ;

ECKBERG, K ;

LLOYD, S ;

PURL, S ;

BLENDOWSKI, C ;

GOODMAN, M ;

BARNICLE, M ;

STEWART, I ;

MCHALE, M ;

BONOMI, P ;

KAPLAN, E ;

TAYLOR, S ;

THOMAS, CR ;

HARRIS, J .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579

[6]

Charalambous A, 2017, SAGE OPEN MED, V5, DOI 10.1177/2050312117717507

[7] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].

Cheang, Maggie C. U. ;

Chia, Stephen K. ;

Voduc, David ;

Gao, Dongxia ;

Leung, Samuel ;

Snider, Jacqueline ;

Watson, Mark ;

Davies, Sherri ;

Bernard, Philip S. ;

Parker, Joel S. ;

Perou, Charles M. ;

Ellis, Matthew J. ;

Nielsen, Torsten O. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750

[8] PROGNOSTIC VALUE OF QUALITY-OF-LIFE SCORES DURING CHEMOTHERAPY FOR ADVANCED BREAST-CANCER [J].

COATES, A ;

GEBSKI, V ;

SIGNORINI, D ;

MURRAY, P ;

MCNEIL, D ;

BYRNE, M ;

FORBES, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (12) :1833-1838

[9]

Dancey J, 1997, QUAL LIFE RES, V6, P151

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 4 →